Genentech's Evrysdi Two-Year Data Shows Promising Results In Spinal Muscular Atrophy, Most Children Treated Early Reach Key Mobility Milestones
Genentech's Evrysdi Two-Year Data Shows Promising Results In Spinal Muscular Atrophy, Most Children Treated Early Reach Key Mobility Milestones
罕见疾病治疗方面的权威Genentech公布了Evrysdi两年数据，显示在脊髓性肌萎缩症患儿中，早期治疗的大多数儿童达到了重要的运动里程碑。
– Positive data confirm Evrysdi efficacy and safety in children first treated pre-symptomatically before 6 weeks of age, with most achieving motor milestones similar to children without SMA –
– 正面数据证实 Evrysdi 在婴儿6周大之前预症状治疗的儿童中的疗效和安全性，大多数实现了类似于没有SMA的儿童的运动里程碑 –
– All children were able to swallow and feed orally, with none requiring permanent ventilation –
– 所有儿童能够吞咽和口服进食，没有需要永久通气的 –
– Evrysdi is the only non-invasive SMA therapy and is approved in over 100 countries, with more than 16,000 people with SMA treated globally –
– Evrysdi 是唯一的非侵入性SMA治疗药物，在100多个国家获批，全球治疗SMA的人数超过16,000人 –